Jonathan Ginns, MD
Adult Congenital Heart Disease · Austin, TXNPI 1962737692
Payments from drug & device makers
Across 221 payments — averaging $966.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$198K
- Boston Scientific$12K
- Abbott$2K
- Bristol Myers Squibb$300
- Pfizer$276
- Novartis$271
- plus $1K from 20 others
What the payments were for
- Consulting fees$1,8002%
- Speaking & faculty fees$86,21474%
- Travel & lodging$22,31219%
- Food & beverage$6,6336%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 92 | $197,507 |
| Boston Scientific | 17 | $11,814 |
| Abbott | 34 | $1,956 |
| Bristol Myers Squibb | 1 | $300 |
| Pfizer | 10 | $276 |
| Novartis | 15 | $271 |
| Cvrx, Inc. | 8 | $244 |
| Alnylam Pharmaceuticals Inc. | 8 | $215 |
| Abiomed | 3 | $170 |
| Medtronic | 1 | $166 |
| Bayer | 7 | $152 |
| Amgen | 5 | $84 |
| Novo Nordisk | 3 | $68 |
| Edwards Lifesciences | 1 | $65 |
| Impulse Dynamics (USA) Inc. | 3 | $55 |
| Heartflow, Inc. | 1 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $38 |
| AstraZeneca | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| GE HealthCare | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| Atricure, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$110,630
- CARDIOMEMS$492
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$405
- COREVALVE EVOLUT R$166
- Confirm Rx$153
- MitraClip System$143
- HeartMate 3 Left Ventricular Assist Device$140
- MitraClip$133
- Impella$107
- Barostim Neo System$100
How this compares
Too few adult congenital heart disease providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $118,857 |
| CamzyosMavacamten | 11 | $91,915 |
| XareltoRivaroxaban | 19 | $29,640 |
| EntrestoSacubitril/Valsartan | 26 | $26,134 |
| Repatha SureclickEvolocumab | 21 | $16,652 |
| Atorvastatin Calcium | 370 | $3,593 |
| Metoprolol Succinate | 199 | $3,240 |
| Rosuvastatin Calcium | 236 | $3,227 |
| Losartan Potassium | 191 | $2,306 |
| Ezetimibe | 102 | $1,941 |
| Potassium Chloride | 71 | $1,559 |
| Amlodipine Besylate | 248 | $1,466 |
| Lisinopril | 130 | $1,252 |
| Spironolactone | 116 | $1,010 |
| Valsartan | 16 | $882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $276 | $118,85788 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $197,507 | $91,91511 claims |
| NovartisEntresto | $271 | $26,13426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult congenital heart disease providers in Texason file to place this against a meaningful peer group, so we don't.
Other adult congenital heart disease in Austin
- Santosh UppuHouston$7K
- Stephen DolgnerHouston$669
- Tony PastorHouston$649
- Katherine KearneyDallas$600
- Anna VenardosFort Worth$192
- Mary BricknerDallas$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.